Fasidotril Eli Lilly

Fatih Ozdener; Vural Ozdemir

Fasidotril Eli Lilly

Fatih Ozdener, Vural Ozdemir

Tıbbi Farmakoloji

Araştırma sonucu: Dergi katkısı › Derleme makalesi › bilirkişi

3 Alıntılar (Scopus)

Özet

Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe.

Orijinal dil	İngilizce
Sayfa (başlangıç-bitiş)	1113-1119
Sayfa sayısı	7
Dergi	Current Opinion in Investigational Drugs
Hacim	4
Basın numarası	9
Yayın durumu	Yayınlanan - Eyl 2003

Diger dosyalar ve linkler

Link to publication in Scopus

Bundan alıntı yap

@article{46722211fc1242d68a0aa6d02ddfdb83,

title = "Fasidotril Eli Lilly",

abstract = "Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe.",

author = "Fatih Ozdener and Vural Ozdemir",

year = "2003",

month = sep,

language = "English",

volume = "4",

pages = "1113--1119",

journal = "Current Opinion in Investigational Drugs",

issn = "1472-4472",

publisher = "Current Drugs Ltd.",

number = "9",

}

TY - JOUR

T1 - Fasidotril Eli Lilly

AU - Ozdener, Fatih

AU - Ozdemir, Vural

PY - 2003/9

Y1 - 2003/9

N2 - Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe.

AB - Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe.

UR - http://www.scopus.com/inward/record.url?scp=0142245364&partnerID=8YFLogxK

M3 - Review article

C2 - 14582457

AN - SCOPUS:0142245364

SN - 1472-4472

VL - 4

SP - 1113

EP - 1119

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

IS - 9

ER -

Fasidotril Eli Lilly

Özet

Diger dosyalar ve linkler

Parmak izi

Bundan alıntı yap